TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12668792
Drug: Salbutamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (15 micro g/kg over 20 minutes)
Study: 12668792
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg over 20 minutes)
Study: 30649227
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg BID
Study: 23313581
Drug: Intranasal vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal vasopressin (AVP) 20 IU
Study: 20493637
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) 24 IU
Study: 22902348
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg orally once daily starting on cycle day 8 until follicle rupture or onset of next menses)
Study: 22902348
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg orally once daily starting with LH surge for 6 days)
Study: 19281728
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg tablet (test formulation)
Study: 19281728
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg tablet (reference formulation)
Study: 15679233
Drug: Pristinamycin 1
Normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin 1 g bid for 4 days
Study: 15679233
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg bid for 5 days
Study: 3109088
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) starting one week prior to transplant
Study: 3109088
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with a 5% dextrose solution containing electrolytes, minerals, trace elements, and vitamins (Control)
Study: 28891743
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - Treatment as usual
Study: 26665571
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 µg i.v.
Study: 24160333
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) plus intercourse for six cycles
Study: 24160333
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) plus IUI for six cycles
Study: 24160333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CC only)
Study: 21167339
Drug: Female sex
Normalized name: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female sex associated with a 23% (or 13-minute) increase in time from hospital arrival to reperfusion therapy.
Study: 12893503
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (16 sessions of Short Psychodynamic Supportive Psychotherapy) and pharmacotherapy (fluoxetine, amitriptyline, and moclobemide)
Study: 10886311
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose methylprednisolone treatment for 15 days
Study: 8312196
Drug: Intervention cytoreduction
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention cytoreduction after 3 cycles of chemotherapy
Study: 8312196
Drug: 3 further
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 further cycles of chemotherapy
Study: 3087701
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition solution supplemented with 44.6% branched-chain amino acids (BCAA)
Study: 3087701
Drug: Standard total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard total parenteral nutrition (19.0% BCAA)
Study: 20573926
Drug: Carboplatin-paclitaxel (chemotherapy)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-paclitaxel (chemotherapy)
Study: 19088832
Drug: Beta-adrenoceptor blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blockers
Study: 12942401
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg twice per day
Study: 12942401
Drug: Azithromycin, 500
Normalized name: Azithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 500 mg once per day
Study: 10789592
Drug: IFN-alpha-2a, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha-2a, 6 MIU s.c. TIW for 4 weeks, followed by 3 MIU s.c. TIW, and 13-cis-retinoic acid 1 mg/kg/day p.o. BID daily
Study: 10789592
Drug: Trophosphamide 100-150
Normalized name: cyclophosphamide 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophosphamide 100-150 mg/day p.o. BID
Study: 10789592
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance treatment (Control group)
Study: 8262820
Drug: BFM chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFM chemotherapy with 1800 cGy cranial irradiation
Study: 8262820
Drug: LSA2L2 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSA2L2 chemotherapy with 1800 cGy cranial irradiation and 1500 cGy to nonabdominal bulk disease
Study: 22222856
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg BHT-3009
Study: 22222856
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg BHT-3009
Study: 18567749
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isoflavones (ISO)
Study: 14643954
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with a fraction dose of 1.8 Gy to a median total dose of 54 Gy
Study: 1657199
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (0.15 mg)
Study: 6401510
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance treatment with cimetidine
Study: 26883504
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention (home-based exercise program 3 times a week + physical therapy once every 2 weeks for 14 weeks)
Study: 26883504
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care physical therapy (physical therapy twice a week + home-based exercise program once a week for 14 weeks)
Study: 25028463
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (RHZE thrice weekly)
Study: 7539544
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg hyoscine N-butyl bromide
Study: 1970460
Drug: Nifedipine 1
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 1 mg i.v. with atracurium
Study: 1970460
Drug: Nifedipine 1
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 1 mg i.v. during continuous relaxation with atracurium or vecuronium
Study: 1970460
Drug: Nifedipine 1
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 1 mg i.v. at the end of anesthesia
Study: 7019558
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution (0.1% - 0.5%)
Study: 28651793
Drug: IM+oral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM+oral therapy (intramuscular + daily oral)
Study: 28651793
Drug: Daily oral-only
Normalized name: Daily Hist Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral-only therapy
Study: 21866096
Drug: GSK1018921 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1018921 (0.5 to 280 mg)
Study: 19265025
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Study: 19265025
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Study: 19265025
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks, then 20 mg rosuvastatin from weeks 6 to 12
Study: 9574890
Drug: High allergen
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High allergen content NRL gloves with skin protection cream
Study: 9574890
Drug: Low allergen
Normalized name: Black Willow Allergen Extract 0.05 GM/1 ML Subcutaneous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low allergen content NRL gloves with skin protection cream
Study: 8166094
Drug: Manual toothbrushing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrushing with standard fluoride toothpaste and daily use of a 0.05% sodium fluoride rinse
Study: 29630721
Drug: Yimitasvir phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir phosphate 30 mg
Study: 29630721
Drug: Yimitasvir phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir phosphate 100 mg
Study: 29630721
Drug: Yimitasvir phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir phosphate 200 mg
Study: 21514589
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (3.0 g/d)
Study: 14730218
Drug: Clarithromycin (CAM)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CAM) 400 mg/day orally for 14 days prior to surgery and for 7 days following surgery, in addition to flomoxef
Study: 14730218
Drug: Flomoxef (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomoxef (control group) administered for 4-7 days following surgery
Study: 10150185
Drug: Trimetazidine 1
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 1 mg.kg‐1
Study: 10150185
Drug: Trimetazidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 1.5 mg.kg‐1
Study: 3067546
Drug: CV 205-502
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CV 205-502 (0.05 micrograms daily)
Study: 23832397
Drug: MSC1992371A administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC1992371A administered on days 1 and 8 (schedule 1)
Study: 23832397
Drug: MSC1992371A administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC1992371A administered on days 1, 2, and 3 (schedule 2)
Study: 23832397
Drug: MSC1992371A administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC1992371A administered on days 1-3 and 8-10 (schedule 3)
Study: 20609183
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) at 1.8 g/day for 12 months
Study: 16383032
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 50 g/L CISS, 2,000 ml per day (Group A)
Study: 16383032
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 50 g/L glucose, 2,000 ml per day (Group B)
Study: 12394711
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (900 mg, 3 times daily)
Study: 10088031
Drug: Levocabastine nasal
Normalized name: levocabastine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine nasal spray (0.2 mg twice daily)
Study: 2259928
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate (800 mg per day)
Study: 2259928
Drug: Standard-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose megestrol acetate (160 mg per day)
Study: 2259925
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate
Study: 2259928
Drug: Standard-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose megestrol acetate
Study: 42529
Drug: Intranasal LH-RH
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal LH-RH
Study: 19265745
Drug: Diaphragm plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm plus placebo gel hydroxyethyl cellulose (HEC)
Study: 19265745
Drug: Gel-diaphragm users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-diaphragm users
Study: 19265745
Drug: Gel-only users
Normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-only users
Study: 17479444
Drug: Combined T3/T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined T3/T4 therapy
Study: 11742168
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type-A (Botox) injection - 10 units to each side of the puborectalis or 20 units to the posterior aspect of this muscle.
Study: 11742168
Drug: Further injections
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further injections of Botox (1-5 every 3 months) for those who did not respond to the first injection.
Study: 9537613
Drug: Iron glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron glycine (1.4 mg added Fe/serving)
Study: 9537613
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (1.4 mg added Fe/serving)
Study: 8018689
Drug: 7 weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 weekly sessions on nutrition and behavior modification
Study: 31591130
Drug: NTM-1634 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1634 at 0.33 mg/kg
Study: 31591130
Drug: NTM-1634 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1634 at 0.66 mg/kg
Study: 31591130
Drug: NTM-1634 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1634 at 1 mg/kg
Study: 26012700
Drug: Web-based prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based prostate cancer treatment decision aid (DA) offered after diagnosis.
Study: 18177867
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day letrozole
Study: 18177867
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day clomiphene citrate (CC)
Study: 17209177
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + Vitamin D supplement (600 mg elemental calcium and 200 IU vitamin D/tablet, 2 tablets/d)
Study: 17209177
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + Vitamin D supplement
Study: 14987190
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise therapy programme
Study: 26168681
Drug: Rengalin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rengalin (2 tablets 3 times daily for 3 days, then half dose for 4 days)
Study: 26168681
Drug: Codelac (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codelac (1 tablet 3 times daily for 7 days)
Study: 18381567
Drug: MC-1, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-1, 250 mg/d
Study: 12747229
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 10 mg of dexamethasone phosphate in two doses at an interval of 12 hours
Study: 346153
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (antifibrinolytic agent) for six weeks after rupture of an intracranial aneurysm
Study: 346153
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antifibrinolytic treatment)
Study: 31304912
Drug: Anaesthetic-analgesic ear
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic-analgesic ear drops
Study: 28229980
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with oral iron supplementation
Study: 28229980
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation with acupuncture
Study: 28229980
Drug: Sham-acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-acupuncture combined with oral iron supplementation
Study: 23807360
Drug: Human RV
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human RV vaccine (RIX4414)
Study: 21849007
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 15 mg qd (up-titrated to 30 mg after 6 weeks)
Study: 21849007
Drug: Sitagliptin/Metformin (SITA/MET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/Metformin (SITA/MET) (up-titrated to 50/1000 mg bid over 4 weeks)
Study: 21849007
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) (up-titrated to 45 mg qd)
Study: 15005812
Drug: Psyllium-based supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium-based supplement (1 tablespoon with 8 oz of water, twice daily for 4 days)
Study: 11355932
Drug: Blocking P‐glycoprotein‐mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking P‐glycoprotein‐mediated drug efflux
Study: 7714551
Drug: PCNU 75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCNU 75-100 mg/m2 IV every 8 weeks
Study: 7714551
Drug: AZQ 15
Normalized name: AZQ
DrugBank: Diaziquone (DB17174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZQ 15 mg/m2 IV once a week for 4 weeks, every 6-8 weeks
Study: 24353020
Drug: Red morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red morphine drops (RMD) - 1/12 of their 24-hour morphine dose
Study: 24353020
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (SCM) - 60 percent of their 24-hour morphine dose
Study: 17645558
Drug: RSG/GLIM FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/GLIM FDC regimen A (4 mg/4 mg OD maximal)
Study: 17645558
Drug: RSG/GLIM FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/GLIM FDC regimen B (8 mg/4 mg OD maximal)
Study: 17645558
Drug: RSG (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG (8 mg OD maximal)
Study: 17645558
Drug: GLIM (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLIM (4 mg OD maximal)
Study: 12800456
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS formulation
Study: 8841156
Drug: Vancomycin therapeutic
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin therapeutic drug monitoring (TDM) group (n = 37)
Study: 8841156
Drug: Vancomycin therapeutic
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin therapeutic drug monitoring (TDM)
Study: 3154698
Drug: Molsidomine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (4 mg)
Study: 1478400
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg) followed by Molsidomine (4 mg)
Study: 2858145
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg/kg and Vecuronium 0.005 mg/kg
Study: 2858145
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg/kg and Vecuronium 0.01 mg/kg
Study: 2858145
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg/kg and Vecuronium 0.015 mg/kg
Study: 25132158
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (50 mg.kg(‐1) followed by a continuous infusion of 15 mg.kg(‐1) .h(‐1))
Study: 22584952
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g of chocolate containing 80% cacao
Study: 20432513
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (donation-as-usual condition)
Study: 12182385
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccine (HbOC)
Study: 7801861
Drug: Colestipol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 10 g and lovastatin 20 mg/day (C10 + L20)
Study: 7801861
Drug: Colestipol 5
Normalized name: colestipol 5 g oral granule for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 5 g and lovastatin 20 mg/day (C5 + L20)
Study: 7801861
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg/day (L40)